In this segment, Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, remark on the financial burden of Clostridium difficile, highlighting recurrent disease as a contributing factor and, consequently, considering the cost-effectiveness of treating appropriate candidates with fidaxomicin.

свернуть